Despite this evidence in experimental in vitro and in vivo models, conflicting data have been obtained in human patients with NAFLD, regarding the role of leptin in hepatic inflammation and fibrosis (Polyzos et al., 2015); this has been a major obstacle in testing leptin therapy for this disease. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.